The Medical Cost of Depressed Outpatients in Shanghai and 6-month Follow-up Study with Treatment of Paroxetine

Wenjuan LIU,Jianlin JI,Wenyuan WU,Yijue SHI,Chongshun WANG,Xingbao CHEN
DOI: https://doi.org/10.3969/j.issn.1008-6358.2007.02.060
2007-01-01
Abstract:Objective: It aims to investigate the use of antidepressants and the annual economic burden among depressed outpatients in Shanghai, and to assess the quality of life (QOL) and effectiveness of paroxetine on depression. Methods: It was a multi-center collaborative clinical trial and 652 major depressed cases were inquired for economic burden and drug treatment investigation. There were 180 outpatients treated with paroxetine and assessed with HAMD, HAMA and SF-36 before and after treatment. Results: (1)SSRIs were most common used for treatment of depression in clinical practice now (90. 18%). (2) The total economic burden of depressed outpatients in shanghai was estimated about 133 million RMB a year(values in 2003), and a-bout a half of them for direct medical costs. 3) The depressed patients had a poor QOL (score less than 50), but after treatment, they had a great improvement in QOL (scores over 70) and depressive and anxiety symptoms. Conclusion:Depression as a mental disorder can create a huge burden on the patient themselves, their families, and the society. If antidepressant was given as soon as possible, the QOL and associated depressive and anxiety symptoms will be improved obviously among the depressed outpatients.
What problem does this paper attempt to address?